The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib.
10.4046/trd.2015.78.4.315
- Author:
Dong Il PARK
1
;
Sun Young KIM
;
Ju Ock KIM
;
Sung Soo JUNG
;
Hee Sun PARK
;
Jae Young MOON
;
Chae Uk CHUNG
;
Song Soo KIM
;
Jae Hee SEO
;
Jeong Eun LEE
Author Information
1. Division of Pulmonary, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea. vov-x@daum.net
- Publication Type:Original Article
- Keywords:
EGFR Tyrosine Kinase Inhibitor;
Gefitinib;
Carcinoma, Non-Small Cell Lung;
Progression-Free Survival
- MeSH:
Adenocarcinoma;
Carcinoma, Non-Small-Cell Lung*;
Disease-Free Survival*;
Drug Therapy;
Humans;
Linear Models;
Medical Records;
Protein-Tyrosine Kinases;
Receptor, Epidermal Growth Factor;
Retrospective Studies;
Smoke;
Smoking
- From:Tuberculosis and Respiratory Diseases
2015;78(4):315-320
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or progression-free survival (PFS). However, there are some patients harboring sensitive EGFR mutations who responded poorly to EGFR-TKI therapy. In addition, there is variability in the PFS after EGFR-TKI treatment. METHODS: We performed a retrospective analysis of the medical records of 85 patients with non-small cell lung cancer, who had achieved a stable disease or better response at the first evaluation of treatment response, after receiving a 2-month course of gefitinib. We calculated the tumor shrinkage rate (TSR) by measuring the longest and perpendicular diameter of the main mass on computed tomography before, and 2 months after, gefitinib therapy. RESULTS: There was a significant positive correlation between the TSR and PFS (R=0.373, p=0.010). In addition, a simple linear regression analysis showed that the TSR might be an indicator for the PFS (B+/-standard error, 244.54+/-66.79; p=0.001). On univariate analysis, the sex, histologic type, smoking history and the number of prior chemotherapy regimens, were significant prognostic factors. On multivariate regression analysis, both the TSR (beta=0.257, p=0.029) and adenocarcinoma (beta=0.323, p=0.005) were independent prognostic factors for PFS. CONCLUSION: Our results showed that the TSR might be an early prognostic indicator for PFS in patients receiving EGFR-TKI therapy.
